The following table highlights multi-billion dollar deals where established giants moved to buy specialized oncology companies: Target Biotech Value (Up to) Primary Cancer Focus Kelonia Therapeutics $7 Billion Blood Cancer (CAR-T) Abbott Exact Sciences $21 Billion Early Screening/Diagnostics Gilead Tubulis $5 Billion Ovarian & Lung Cancer (ADCs) Gilead Arcellx $7.8 Billion Multiple Myeloma Johnson & Johnson Halda Therapeutics $3.1 Billion Prostate Cancer Genmab Merus $8 Billion Head and Neck Cancer Novartis Synnovation (Pikavation) $3 Billion Breast Cancer Why These Deals are Happening
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more buy cancer
: Companies are specifically targeting "in vivo" CAR-T therapies (which modify cells inside the body) and Antibody-Drug Conjugates (ADCs), which act like "guided missiles" to kill tumors while sparing healthy tissue. Learn more : Companies are specifically targeting "in
: Large firms like Eli Lilly and Novartis are racing to replace revenue from older drugs that are nearing patent expiration. Investment Outlook Novartis to Buy Breast-Cancer Drug From
: Abbott's $21B move for Exact Sciences highlights a growing market for early detection through blood and stool tests. Investment Outlook
Novartis to Buy Breast-Cancer Drug From Synnovation ... - WSJ